Investigating treatment resistance in pancreatic cancer using patient-derived organoids.
Official title: Core 2: Human Specimen and Organic Core (HSO Core)
Funded at Salk Institute for Biological Studies · NIH-10883579 · Data updated 2026-11-12
This study is looking at why some patients with pancreatic cancer don't respond well to treatments, and it will use special lab-grown models of tumors to test different drug combinations to find better ways to help them.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Salk Institute for Biological Studies NIH-funded |
| Lab location | 1 site (La Jolla, UNITED STATES) |
| Project start | July 6, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $456,888 |
| NIH project number | 5P01CA265762-02 |
| Project ID | NIH-10883579 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who are facing challenges with treatment response.
✕Less likely to help
Patients with other types of cancer or those not diagnosed with pancreatic ductal adenocarcinoma may not benefit from this research.
What this research studies
This research focuses on understanding why patients with pancreatic ductal adenocarcinoma (PDA) often do not respond to treatments or quickly develop resistance. The team will create three-dimensional organoid models derived from patient samples, which mimic the characteristics of human tumors. These organoids will be used to test various drug combinations and identify effective therapies. By studying these models, researchers aim to uncover the mechanisms behind treatment resistance and develop better therapeutic strategies.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer patients, improving their chances of response to therapy.
How similar studies have gone: Previous research using patient-derived organoids has shown promise in understanding cancer treatment responses, indicating that this approach could be effective.
Where this research is happening
-
Salk Institute for Biological Studies
La Jolla, United States Active
Researchers
- Principal investigator: Tiriac, Herve — Salk Institute for Biological Studies
- Study coordinator: Tiriac, Herve
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.